Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
262.7 USD -0.53% Intraday chart for Amgen Inc. -2.71% -8.80%
Apr. 17 UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating MT
Apr. 16 Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease MT

Business Summary

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:

- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;

- other (5.8%): primarily royalties.

The United States account for 70.3% of net sales.

Number of employees: 26,700

Sales per Business

USD in Million2022Weight2023Weight Delta
Human Therapeutics
95.5 %
24,801 94.2 % 26,910 95.5 % +8.50%
Other
4.5 %
1,522 5.8 % 1,280 4.5 % -15.90%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
70.3 %
18,595 70.6 % 19,806 70.3 % +6.51%
Rest of World
29.6 %
7,655 29.1 % 8,337 29.6 % +8.91%
Canada
0.2 %
73 0.3 % 47 0.2 % -35.62%

Managers

Managers TitleAgeSince
Robert Bradway CEO
 Chief Executive Officer 61 06-05-31
Peter Griffith DFI
 Director of Finance/CFO 65 19-10-22
James Bradner CTO
 Chief Tech/Sci/R&D Officer 52 Dec. 17
Jean-Charles Soria CTO
 Chief Tech/Sci/R&D Officer 53 -
Esteban Santos COO
 Chief Operating Officer 56 06-12-31
Nancy Grygiel CMP
 Compliance Officer 56 14-12-31
Mike Zahigian CTO
 Chief Tech/Sci/R&D Officer - 00-12-31
David Reese CTO
 Chief Tech/Sci/R&D Officer 61 04-12-31
Darryl Sleep CTO
 Chief Tech/Sci/R&D Officer - 18-07-31
Paul Burton CTO
 Chief Tech/Sci/R&D Officer 55 23-05-31

Members of the board

Members of the board TitleAgeSince
Charles Holley BRD
 Director/Board Member 67 17-02-02
Ellen Kullman BRD
 Director/Board Member 68 16-10-13
Robert Williams BRD
 Director/Board Member 75 14-10-16
Robert Eckert BRD
 Director/Board Member 69 02-12-31
Ronald Sugar BRD
 Director/Board Member 75 10-07-21
Robert Bradway CEO
 Chief Executive Officer 61 06-05-31
Wanda Austin BRD
 Director/Board Member 69 17-10-23
Tyler Jacks BRD
 Director/Board Member 63 11-12-31
Omar Ishrak BRD
 Director/Board Member 68 21-07-29
Greg Garland BRD
 Director/Board Member 66 13-10-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 535,918,901 534,604,713 ( 99.75 %) 0 99.75 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.151 %
49,042,553 9.151 % 13 944 M $
BlackRock Advisors LLC
6.544 %
35,071,116 6.544 % 9 971 M $
STATE STREET CORPORATION
5.498 %
29,463,970 5.498 % 8 377 M $
PRIMECAP Management Co.
2.723 %
14,591,468 2.723 % 4 149 M $
Eaton Vance Management
2.693 %
14,434,061 2.693 % 4 104 M $
Geode Capital Management LLC
2.303 %
12,339,956 2.303 % 3 508 M $
ishares (DE) Invag Mit Teilgesellschaftsvermogen
2.185 %
11,711,407 2.185 % 3 330 M $
Charles Schwab Investment Management, Inc.
1.939 %
10,393,110 1.939 % 2 955 M $
Wells Fargo Bank NA
1.766 %
9,463,053 1.766 % 2 691 M $
Lee Munder Investments Ltd.
1.321 %
7,080,253 1.321 % 2 013 M $
NameEquities%Valuation
Safra Asset Management Ltda.
0.000460 %
69,000 0.000460 % 695 300 $
Bram Bradesco Asset Management S/A DTVM
0.000230 %
34,524 0.000230 % 347 892 $
BB Gestão de Recursos DTVM SA
0.000221 %
33,151 0.000221 % 334 056 $

Holdings

NameEquities%Valuation
BEIGENE, LTD.
19.82%
 246,269,426 19.82% 2,992,444,422 $
NEUMORA THERAPEUTICS, INC.
22.26%
 35,368,653 22.26% 486,318,979 $
FRAZIER LIFESCIENCES ACQUISITION CORPORATION
5.50%
 4,910,000 5.50% 116,121,500 $
VIGIL NEUROSCIENCE, INC.
8.69%
 3,206,281 8.69% 10,933,418 $
JASPER THERAPEUTICS, INC.
0.67%
 100,993 0.67% 2,965,154 $

Company contact information

Amgen, Inc.

One Amgen Center Drive

91320-1799, Thousand Oaks

+805 447 1000

http://www.amgen.com
address Amgen Inc.(AMGN)

Group companies

NameCategory and Sector
Amgen NV
Logo Amgen NV

Amgen NV

Pharmaceuticals: MajorHealth Technology

Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the private company is Gabor Sztaniszlav.

Pharmaceuticals: Major
Amgen Technology Ltd.
Logo Amgen Technology Ltd.

Amgen Technology Ltd.

BiotechnologyHealth Technology

Part of Amgen, Inc., Amgen Technology Ltd. develops, manufactures and markets human therapeutic products based on cellular biology. The private company is located in Bermuda.

Biotechnology
Amgen Manufacturing Ltd. (Bermuda)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Amgen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
264.1 USD
Average target price
300.3 USD
Spread / Average Target
+13.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AMGEN INC. Stock Amgen Inc.
-8.80% 142B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.58% 554B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 349B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 318B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.96% 210B
NOVARTIS AG Stock Novartis AG
-0.41% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-10.02% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. Company Amgen Inc.